Last updated: March 2026
The FDA removed most semaglutide formulations from its shortage list in late 2024, which means compounding pharmacies can no longer legally produce semaglutide copies. Novo Nordisk reports supply is stable for both Ozempic and Wegovy as of early 2026.
Following the SELECT trial showing Wegovy reduces cardiovascular events by 20%, CMS expanded Medicare Part D coverage to include semaglutide for patients with existing heart disease. This is a major shift from previous obesity-only exclusions.
The FDA approved a higher 25mg dose of oral semaglutide (Rybelsus), bringing the pill form closer to injectable doses in effectiveness. This is significant for patients who prefer not to self-inject.
A landmark study published in Nature Medicine found semaglutide significantly reduced alcohol consumption in people with alcohol use disorder. Trials for FDA approval specifically for AUD are now underway.
The FDA approved Zepbound (tirzepatide) as the first medication specifically for obesity-related obstructive sleep apnea — a major expansion of GLP-1 drug indications beyond weight loss and diabetes.